Pharmacokinetic study of osimertinib in NSCLC patients with body fluid
Not Applicable
Recruiting
- Conditions
- Advanced non-small cell lung cancer
- Registration Number
- JPRN-UMIN000028922
- Lead Sponsor
- Shizuoka cancer center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with interstitial pneumonitis identified by chest X-ray
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The association of malignant effusion with osimertinib exposure in non-small cell lung cancer
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms influence osimertinib distribution in NSCLC patients with pleural effusion?
How does osimertinib pharmacokinetics compare to other EGFR inhibitors in advanced NSCLC with body fluid accumulation?
Which EGFR mutation biomarkers correlate with osimertinib efficacy in NSCLC patients with effusions?
What adverse events are associated with osimertinib in NSCLC patients with fluid retention and how are they managed?
Are there synergistic effects of osimertinib with anti-VEGF therapies in EGFR-mutated NSCLC with body fluid?